Skip to main content
SpringerLink
Log in

Drug Disposition in Obese Humans

An Update

  • Review Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Drug disposition for many drugs has now been studied in obese individuals and some general conclusions can be drawn. Absorption of drugs evaluated to date is unchanged due to obesity. Apparent volume of distribution is greatly increased for some drugs including most benzodiazepines, thiopentone, phenytoin, verapamil and lignocaine (lidocaine). Modest increases in volume of distribution have been noted for methylxanthines, aminoglycosides, vancomycin, ibuprofen, prednisolone and heparin. Distribution of digoxin, cimetidine and procainamide is unchanged in obesity. The mechanism for the increased distribution of some drugs and unchanged distribution of others in obesity is unclear at present. It may be in part due to the lipophilic character of the drug molecule; however, other complex and as yet poorly understood factors contribute to the variability in drug distribution in obese patients.

Protein binding of drugs bound to albumin is not dramatically changed in obesity. In contrast, some studies report that drugs bound to α1-acid glycoprotein (AAG) may have increased binding that is related to increased serum AAG concentration; however, this is not a consistent finding.

Oxidative drug biotransformation is minimally changed in obesity with the exceptions of ibuprofen and prednisolone, for which clearance increases as a highly correlated function of total bodyweight. Drug conjugation uniformly increases as a function of bodyweight in obesity, with paracetamol (acetaminophen), lorazepam and oxazepam having been studied. Drug acetylation may be unchanged in obesity, with only procainamide evaluated at this time. High clearance drugs, including lignocaine, verapamil and midazolam, have no change in clearance in obese individuals compared to normal bodyweight controls. Renal clearance of drugs is little changed for some drugs evaluated (digoxin, cimetidine), and increased for others (aminoglycosides, unmetabolised procainamide).

Characterisation of appropriate animal models of obesity is underway to clarify the mechanisms for these in vivo pharmacokinetic observations in obese man. Two models, the Zucker obese and the obese cafeteria-fed male Sprague-Dawley rat, have provided preliminary physiological pharmacokinetic data with evaluations of theophylline, phenobarbitone and verapamil. The Zucker genetically obese rat may be somewhat limited as a model due to impairment in renal function and impairment in capacity for regulation of cytochrome P-450 activity in obese animals that differs from heterozygous lean Zucker rats. Limitations of the cafeteria-fed Sprague-Dawley rat model of obesity identified to date are that only male rats will eat to a significant extent of obesity, the alteration in animal diet required to achieve obesity is difficult to properly control in pharmacokinetic studies in which dietary alteration in man and animals is well known to change oxidative drug clearance, and that at least 3 months of feeding the specialised diet are required to achieve bodyweight at least 40% in excess of control animals. With further identification and understanding of the limitations of these models, a mechanistic understanding of pharmacokinetic alterations associated with human obesity may be forthcoming.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abernethy DR, Divoll M, Greenblatt DJ, Ameer B. Obesity, sex, and acetaminophen disposition. Clinical Pharmacology and Therapeutics 31: 783–790, 1982

    Article  PubMed  CAS  Google Scholar 

  • Abernethy DR, Greenblatt DJ. Pharmacokinetics of drugs in obesity. Clinical Pharmacokinetics 7: 108–124, 1982

    Article  PubMed  CAS  Google Scholar 

  • Abernethy DR, Greenblatt DJ. Lidocaine disposition in obesity. American Journal of Cardiology 53: 1183–1186, 1984

    Article  PubMed  CAS  Google Scholar 

  • Abernethy DR, Greenblatt DJ. Ibuprofen disposition in obesity. Arthritis and Rheumatism 28: 1117–1121, 1985b

    Article  PubMed  CAS  Google Scholar 

  • Abernethy DR, Greenblatt DJ, Divoll M, Harmatz JS, Shader RI. Alterations in drug distribution and clearance due to obesity. J. Pharmacol. Exp. Therap. 217: 681–685, 1981a

    CAS  Google Scholar 

  • Abernethy DR, Greenblatt DJ, Divoll M, Shader RI. Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). Journal of Pharmaceutical Sciences 71: 942–944, 1982b

    Article  PubMed  CAS  Google Scholar 

  • Abernethy DR, Greenblatt DJ, Divoll M, Shader RI. Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen. Journal of Laboratory and Clinical Medicine 101: 873–880, 1983

    PubMed  CAS  Google Scholar 

  • Abernethy DR, Greenblatt DJ, Divoll M, Smith RB, Shader RT. The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. Clin. Pharmacok. 9: 177–183, 1984a

    Article  CAS  Google Scholar 

  • Abernethy DR, Greenblatt DJ, Matlis R, Gugler R. Cimetidine disposition in obesity. American Journal of Gastroenterology 79: 91–94, 1984b

    PubMed  CAS  Google Scholar 

  • Abernethy DR, Greenblatt DJ, Mitchell JR. In vitro indices of drug distribution in obesity. Clinical Pharmacology and Therapeutics 35: 224, 1984c

    Article  Google Scholar 

  • Abernethy DR, Greenblatt DJ, Smith TW. Digoxin disposition in obesity: clinical pharmacokinetic investigation. American Heart Journal 102: 740–744, 1981b

    Article  PubMed  CAS  Google Scholar 

  • Abernethy DR, Schwartz JB, Todd EL, Mitchell JR. Verapamil dynamics and disposition in obese hypertensives. Federation Proceedings 44: 1128, 1985a

    Google Scholar 

  • Abernethy DR, Todd EL, Schwartz JB. Caffeine disposition in obesity. Brit. J. Clin. Pharmacol. 20: 61–66, 1985b

    Article  CAS  Google Scholar 

  • Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. American Journal of Medicine 67: 811–816, 1979

    Article  PubMed  CAS  Google Scholar 

  • Baecke JAH, Burema T, Deurenberg P. Body fatness, relative weight, and frame size in young adults. British Journal of Nutrition 84: 1–6, 1982

    Article  Google Scholar 

  • Bauer LA, Blouin RA, Griffen WO, Record KE, Bell RM. Amikacin pharmacokinetics in morbidly obese patients. American Journal of Hospital Pharmacy 37: 519–522, 1980

    PubMed  CAS  Google Scholar 

  • Bauer LA, Edwards WAD, DeHuger EP, Simonowitz DA. Influence of weight on aminoglycoside pharmacokinetics in normal weight and markedly obese patients. European Journal of Clinical Pharmacology 24: 643–647, 1983

    Article  PubMed  CAS  Google Scholar 

  • Bauer LA, Wareing-Tran C, Edwards WAD, Raisys V, Ferrer L, et al. Cimetidine clearance in the obese. Clinical Pharmacology and Therapeutics 37: 425–430, 1985

    Article  PubMed  CAS  Google Scholar 

  • Benedeck TH, Blouin RAS, McNamara PJ. Serum protein binding and the role of increased alpha-1-acid glycoprotein in moderately obese male subjects. British Journal of Clinical Pharmacology 18: 941–946, 1984

    Article  Google Scholar 

  • Benedek IH, Fiske WD, Griffen WO, Bell RM, Blouin RA, et al. Serum alpha-1-acid glycoprotein and the binding of drugs in obesity. Brit. J. Clin. Pharmacol. 16: 751–754, 1983

    Article  CAS  Google Scholar 

  • Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob. Agents Chemoth. 21: 575–580, 1982

    Article  CAS  Google Scholar 

  • Blouin RA, Mann HJ, Griffen WO, Bauer LA, Record KE. Tobramycin pharmacokinetics in morbidly obese patients. Clinical Pharmacology and Therapeutics 26: 508–512, 1979

    PubMed  CAS  Google Scholar 

  • Blouin RA, Rowse-Brouwer KL, Record KE, Griffen WO, Plezia PM, et al. Amikacin pharmacokinetics in morbidly obese patients undergoing gastric bypass surgery. Clinical Pharmacy 4: 70–72, 1985

    PubMed  CAS  Google Scholar 

  • Bray GA, York DA. Genetically transmitted obesity in rodents. Physiological Reviews 51: 598–646, 1971

    PubMed  CAS  Google Scholar 

  • Brouwer KLR, Kostenbauder HB, McNamara PJ, Blouin RA. Phenobarbital in the genetically obese Zucker rat. I. Pharmacokinetics after acute and chronic administration. J. Pharmacol. Exp. Therap. 231: 649–653, 1984a

    CAS  Google Scholar 

  • Brouwer KLR, Kostenbauder HB, McNamara PJ, Blouin RA. Phenobarbital in the genetically obese Zucker rat. II. In vivo and in vitro assessments of microsomal enzyme induction. J. Pharmacol. Exp. Therap. 231: 654–659, 1984b

    CAS  Google Scholar 

  • Browne TR. Status epileptieus, In Miller RR & Greenblatt DJ (Eds). Drug therapy reviews, Vol. 2, pp. 453–455, New York, Elsevier, North Holland, 1979

    Google Scholar 

  • Bruce A, Andersson M, Arvidsson B, Isaksson B. Body composition: prediction of normal body potassium, body water and body fat in adults on the basis of body height, body weight and age. Scandinavian Journal of Clinical and Laboratory Investigation 40: 461–473, 1980

    Article  PubMed  CAS  Google Scholar 

  • Christoff PB, Conti DR, Naylor C, Jusko WJ. Procainamide disposition in obesity. Drug Intelligence and Clinical Pharmacy 17: 516–522, 1983

    PubMed  CAS  Google Scholar 

  • Colliver JA, Frank S, Frank A. Similarity of obesity indices in clinical studies of obese adults: a factor in analytic study. American Journal of Clinical Nutrition 38: 640–647, 1983

    PubMed  CAS  Google Scholar 

  • de Divitiis O, Fazio S, Petitto M, Maddalena G, Contalde F, et al. Obesity and cardiac function. Circulation 64: 477–482, 1981

    Article  PubMed  Google Scholar 

  • Dionne RE, Bauer LA, Gibson GA, Griffen WO, Blouin RA. Estimating creatinine clearance in morbidly obese patients. American Journal of Hospital Pharmacy 38: 841–844, 1981

    PubMed  CAS  Google Scholar 

  • Doherty JE, Perkins WH, Flanigan WJ. The distribution and concentration of tritiated digoxin in human tissues. Annals of Internal Medicine 66: 116–124, 1967

    PubMed  CAS  Google Scholar 

  • Dorsey JL, Smith JT. Comparison of hepatic cytochrome P-450 levels of obese mice and nonobese mice. Nutrition Reports International 24: 777–783, 1981

    CAS  Google Scholar 

  • Dundee JW. The influence of body weight, sex and age on the dosage of thiopentone. Brit. J. Anaes. 26: 164–173, 1954

    Article  CAS  Google Scholar 

  • Ewy GA, Groves BM, Ball MF, Nimmo L, Jackson B, et al. Digoxin metabolism in obesity. Circulation 44: 810–814, 1971

    Article  PubMed  CAS  Google Scholar 

  • Forbes GB, Welle SL. Lean body mass in obesity. International Journal of Obesity 7: 99–107, 1983

    PubMed  CAS  Google Scholar 

  • Friedman H, Ochs HR, Greenblatt DJ, Shader RI. Tissue distribution of diazepam and its metabolite desmethyldiazepam: a human autopsy study. J. Clin. Pharmacol. 25: 613–615, 1985

    PubMed  CAS  Google Scholar 

  • Gal P, Jusko WJ, Yurchak AM, Franklin BA. Theophylline disposition in obesity. Clinical Pharmacology and Therapeutics 23: 438–444, 1978

    PubMed  CAS  Google Scholar 

  • Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, et al. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 61: 27–35, 1984

    PubMed  CAS  Google Scholar 

  • Greenblatt DJ, Alen MD, Harmatz JS, Shader RI. Diazepam disposition determinants. Clinical Pharmacology and Therapeutics 27: 301–312, 1980

    Article  PubMed  CAS  Google Scholar 

  • Greenblatt DJ, Arendt RM, Abernethy DR, Giles HG, Sellers EM et al. In vitro quantitation of benzodiazepine lipophilicity: relation to in vivo distribution. British Journal of Anaesthesia 55: 985–989, 1983

    Article  PubMed  CAS  Google Scholar 

  • Hubert HR, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham heart study. Circulation 67: 968–977, 1983

    Article  PubMed  CAS  Google Scholar 

  • Ingalls AM, Dickie MM, Snell GD. Obese, new mutation in the mouse. Journal of Heredity 41: 317–318, 1950

    PubMed  CAS  Google Scholar 

  • Jung D, Mayersohn M, Perrier D, Calkins J, Saunders R. Thiopental disposition in lean and obese patients undergoing surgery. Anesthesiology 56: 265–274, 1982

    Google Scholar 

  • Kappas A, Anderson KE, Conney AH, Alvares AP. Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. Clinical Pharmacology and Therapeutics 20: 643–653, 1976

    PubMed  CAS  Google Scholar 

  • Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL. Indices of relative weight and obesity. Journal of Chronic Disease 25: 329–343, 1972

    Article  CAS  Google Scholar 

  • Knapp TR. A methodological critique of the ‘ideal weight’ concept. J. Am. Med. Assoc. 250: 506–510, 1983

    Article  CAS  Google Scholar 

  • Korsager S. Administration of gentamicin to obese patients. International Journal of Clinical Pharmacology, Therapy and Toxicology 18: 549–553, 1980

    CAS  Google Scholar 

  • Litterst CL. In vitro hepatic drug metabolism and microsomal enzyme induction in genetically obese rats. Biochemical Pharmacology 29: 289–296, 1980

    Article  PubMed  CAS  Google Scholar 

  • Martin E, Tozer TN, Sheiner LB, Riegelman S. The clinical pharmacokinetics of phenytoin. Journal of Pharmacokinetics and Biopharmaceutics 5: 579–596, 1977

    PubMed  CAS  Google Scholar 

  • Masoro EJ. Rats as models for the study of obesity. Experimental Aging Research 6: 261–270, 1980

    Article  PubMed  CAS  Google Scholar 

  • Messerli FH. Obesity in hypertension: how innocent a bystander? American Journal of Medicine 77: 1077–1082, 1984

    Article  PubMed  CAS  Google Scholar 

  • Messerli FH, Sundgaard-Riise K, Reisin ED, Dreslinski GR, Ventura HO, et al. Dimorphic cardiac adaptations to obesity and arterial hypertension. Ann. Int. Med. 99: 757–761, 1983

    PubMed  CAS  Google Scholar 

  • Metropolitan Life Insurance Tables. Weights of insured persons in the United States associated with lowest mortality. Statistical Bulletin of the Metropolitan Life Insurance Company [USA] 40: Nov–Dec 1959

  • Milsap RL, Plaisance KI, Jusko WJ. Prednisolone disposition in obese man. Clin. Pharmacol. Therap. 36: 824–831, 1984

    Article  CAS  Google Scholar 

  • Mujais SK, Tarazi RC, Dustan HP, Fouad FM, Bravo EL. Hypertension in obese patients: hemodynamic and volume studies. Hypertension 4: 84–92, 1982

    Article  PubMed  CAS  Google Scholar 

  • Mulder GJ, Weitering JG, Scholtens E, Dawson JR, Pang KS. Extrahepatic sulfation and glucuronidation in the rat in vivo: determination of the hepatic extraction ratio of harmol and the extrahepatic contribution to harmol conjugation. Biochemical Pharmacology 33: 3081–3087, 1984

    Article  PubMed  CAS  Google Scholar 

  • National Institutes of Health Consensus Development Panel on the Health Implications of Obesity. Health implications of obesity: National Institutes of Health consensus development conference statement. Ann. Int. Med. 103: 147–151, 1985

    Google Scholar 

  • Rohrbaugh TM, Danish M, Ragni MC, Yaffe SJ. The effect of obesity on apparent volume of distribution of theophylline. Pediatric Pharmacology 2: 75–83, 1982

    PubMed  CAS  Google Scholar 

  • Rolls BJ, Rowe EA. Dietary obesity: Permanent changes in body weight. Journal of Physiology 272: 2P, 1977

    PubMed  CAS  Google Scholar 

  • Schentag JJ, Cerra FB, Calleri GM, Leising ME, French MA, et al. Age, disease, and cimetidine disposition in healthy subjects and chronically ill patients. Clinical Pharmacology and therapeutics 29: 737–743, 1981

    Article  PubMed  CAS  Google Scholar 

  • Schwartz SN, Prazin GJ, Lyon JA, Ho M, Pascalle AW. A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects. Journal of Infectious Disease 138: 499–505, 1978

    Article  CAS  Google Scholar 

  • Shum L, Jusko WJ. Theophylline disposition in obese rats. J. Pharmacol. Exp. Therap. 228: 380–386, 1984

    CAS  Google Scholar 

  • Simopoulos AP, van Itallie TB. Body weight, health, and longevity. Annals of Internal Medicine 100: 285–295, 1984

    PubMed  CAS  Google Scholar 

  • Sims EAH. Mechanisms of hypertension in the overweight. Hypertension 4 (Suppl. III): III43–III49, 1982

    PubMed  CAS  Google Scholar 

  • Sketris I, Lesar T, Zaske DE, Cipolle RJ. Effect of obesity on gentamicin pharmacokinetics. Journal of Clinical Pharmacology 21: 288–293, 1982

    Google Scholar 

  • Stokholm KH, Brochner-Mortensen J, Holland-Carlsen PF. Increased glomerular filtration rate and adrenocortical function in obese women. Int. J. Obesity 4: 57–63, 1980

    CAS  Google Scholar 

  • Todd EL, Abernethy DR, Mitchell JR. Tissue distribution of ± verapamil in obese and lean Zucker rats. Abstract. Pharmacologist 27(3): 245, 1985

    Google Scholar 

  • Verbeeck RK, Blackburn JL, Loewen GR. Clinical pharmacokinetics of nonsteroidal anti-inflammatory drugs. Clinical Pharmacokinetics 8: 297–331, 1983

    Article  PubMed  CAS  Google Scholar 

  • Vesell ES, Penno MB. Assessment of methods to identify sources of interindividual pharmacokinetic variations. Clinical Pharmacokinetics 8: 378–409, 1983

    Article  PubMed  CAS  Google Scholar 

  • Wallis W, Kutt H, McDowell F. Intravenous diphenylhydantoin in treatment of acute repetitive seizures. Neurology 18: 513–535, 1968

    Article  PubMed  CAS  Google Scholar 

  • Watson PE, Watson ID, Batt RD. Total body water volumes for adult males and females estimated from simple anthropometric measurements. Am. J. Clin. Nutrit. 33: 27–39, 1980

    PubMed  CAS  Google Scholar 

  • Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance. Clin. Pharmacol. Therap. 18: 377–390, 1975

    CAS  Google Scholar 

  • Zucker LM, Zucker TF. Fatty, a new mutation in the rat. Journal of Heredity 52: 275–278, 1961

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Section on Hypertension/Clinical Pharmacology, Baylor College of Medicine, One Baylor Plaza, Room 826E, Houston, TX, 77030, USA

    Darrell R. Abernethy & David J. Greenblatt

  2. Division of Clinical Pharmacology, Tufts University School of Medicine and New England Medical Center Hospital, Boston, USA

    Darrell R. Abernethy & David J. Greenblatt

Authors
  1. Darrell R. Abernethy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David J. Greenblatt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abernethy, D.R., Greenblatt, D.J. Drug Disposition in Obese Humans. Clin-Pharmacokinet 11, 199–213 (1986). https://doi.org/10.2165/00003088-198611030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-198611030-00002

Keywords

Search

Navigation